Similar articles

• Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.

  Kerl K, Prins C, Saurat JH, French LE. Kerl K, et al. Br J Dermatol. 2006 Dec;155(6):1197-200. doi: 10.1111/j.1365-2133.2006.07523.x. Br J Dermatol. 2006. PMID: 17107389
• Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.

  Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L. Roguedas AM, et al. Br J Dermatol. 2005 Mar;152(3):541-4. doi: 10.1111/j.1365-2133.2005.06433.x. Br J Dermatol. 2005. PMID: 15787825
• Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.

  Park MY, Jung HJ, Park JE, Kim YC. Park MY, et al. Eur J Dermatol. 2010 Jul-Aug;20(4):533-4. doi: 10.1684/ejd.2010.0987. Epub 2010 Jun 14. Eur J Dermatol. 2010. PMID: 20542839 No abstract available.
• [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].

  Gamo R, Calzado L, Pinedo F, López-Estebaranz JL. Gamo R, et al. Actas Dermosifiliogr. 2008 May;99(4):291-6. Actas Dermosifiliogr. 2008. PMID: 18394405 Review. Spanish.
• Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.

  Seker M, Ustaalioğlu BB, Bilici A, Yildirim ME, Kefeli U, Barisik NO, Tamer I, Gumus M. Seker M, et al. Leuk Res. 2010 Jul;34(7):e160-3. doi: 10.1016/j.leukres.2010.02.013. Epub 2010 Mar 12. Leuk Res. 2010. PMID: 20219245 Review. No abstract available.